Assessment of disease progression in motor neuron disease

Jennica M C Winhammar, Dominic B. Rowe, Robert D. Henderson, Matthew C. Kiernan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

64 Citations (Scopus)

Abstract

Motor neuron disease (MND) is characterised by progressive deterioration of the corticospinal tract, brainstem, and anterior horn cells of the spinal cord. There is no pathognomonic test for the diagnosis of MND, and physicians rely on clinical criteria - upper and lower motor neuron signs - for diagnosis. The presentations, clinical phenotypes, and outcomes of MND are diverse and have not been combined into a marker of disease progression. No single algorithm combines the findings of functional assessments and rating scales, such as those that assess quality of life, with biological markers of disease activity and findings from imaging and neurophysiological assessments. Here, we critically appraise developments in each of these areas and discuss the potential of such measures to be included in the future assessment of disease progression in patients with MND.

Original languageEnglish
Pages (from-to)229-238
Number of pages10
JournalLancet Neurology
Volume4
Issue number4
DOIs
Publication statusPublished - 1 Apr 2005
Externally publishedYes

Fingerprint Dive into the research topics of 'Assessment of disease progression in motor neuron disease'. Together they form a unique fingerprint.

Cite this